Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4.

The article "Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4" published in Diabetes, Obesity & Metabolism explores the impact of sotagliflozin on hemoglobin levels in patients with type 2 diabetes and chronic kidney disease. The study found that sotagliflozin increased hemoglobin levels in patients with moderate-severe CKD, regardless of the presence of anemia at baseline. The results suggest that sotagliflozin could be beneficial in managing anemia in this population, in addition to its known cardiorenal protective effects. [Extracted from the article]